IRIS Institutional Research Information System - OPENBS Open Archive UniBS

BERRUTI, ALFREDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 33.782
AS - Asia 15.693
EU - Europa 11.368
SA - Sud America 3.501
AF - Africa 343
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 18
Totale 64.738
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 33.344
SG - Singapore 5.668
CN - Cina 4.931
BR - Brasile 2.900
UA - Ucraina 2.772
HK - Hong Kong 1.860
DE - Germania 1.590
IT - Italia 1.548
VN - Vietnam 1.201
PL - Polonia 969
FI - Finlandia 820
FR - Francia 777
RU - Federazione Russa 699
GB - Regno Unito 696
TR - Turchia 608
IE - Irlanda 520
IN - India 347
AR - Argentina 234
BD - Bangladesh 213
CA - Canada 209
EE - Estonia 191
SE - Svezia 147
ID - Indonesia 145
MX - Messico 139
IQ - Iraq 135
NL - Olanda 120
ZA - Sudafrica 120
JP - Giappone 117
CZ - Repubblica Ceca 113
ES - Italia 93
EC - Ecuador 92
AT - Austria 66
SA - Arabia Saudita 61
PK - Pakistan 59
BE - Belgio 56
VE - Venezuela 56
CO - Colombia 52
MA - Marocco 50
PY - Paraguay 50
UZ - Uzbekistan 49
CL - Cile 48
AE - Emirati Arabi Uniti 35
EG - Egitto 31
AU - Australia 29
NG - Nigeria 29
KE - Kenya 28
DZ - Algeria 27
LT - Lituania 27
CH - Svizzera 26
PE - Perù 26
JO - Giordania 24
KZ - Kazakistan 23
UY - Uruguay 22
AZ - Azerbaigian 21
JM - Giamaica 20
TN - Tunisia 20
AL - Albania 19
KR - Corea 19
NP - Nepal 19
PH - Filippine 19
LB - Libano 18
IL - Israele 17
CR - Costa Rica 16
EU - Europa 16
PT - Portogallo 16
BO - Bolivia 15
BG - Bulgaria 13
DK - Danimarca 13
PA - Panama 13
RO - Romania 12
HN - Honduras 11
ET - Etiopia 10
IR - Iran 10
TT - Trinidad e Tobago 10
KG - Kirghizistan 9
LV - Lettonia 9
TW - Taiwan 9
GR - Grecia 8
HU - Ungheria 8
MY - Malesia 8
OM - Oman 8
PS - Palestinian Territory 8
TH - Thailandia 8
BH - Bahrain 7
BB - Barbados 6
DO - Repubblica Dominicana 6
MK - Macedonia 6
CY - Cipro 5
MD - Moldavia 5
MU - Mauritius 5
NO - Norvegia 5
SK - Slovacchia (Repubblica Slovacca) 5
SN - Senegal 5
SY - Repubblica araba siriana 5
AM - Armenia 4
GE - Georgia 4
GY - Guiana 4
KW - Kuwait 4
LK - Sri Lanka 4
RS - Serbia 4
Totale 64.678
Salva come PNG Salva come JPEG
Città #
Fairfield 4.232
Woodbridge 3.240
Singapore 2.930
Ashburn 2.891
Houston 2.219
Jacksonville 1.880
Hong Kong 1.853
Seattle 1.742
Cambridge 1.595
Wilmington 1.379
Ann Arbor 1.362
Beijing 1.244
The Dalles 1.080
Warsaw 954
San Jose 920
Princeton 879
New York 740
Chandler 728
Los Angeles 605
Helsinki 579
Dallas 547
Chicago 503
Lauterbourg 490
Dublin 477
Nanjing 473
Istanbul 470
Ho Chi Minh City 411
Munich 301
Council Bluffs 295
Brescia 266
Buffalo 252
Des Moines 234
Redondo Beach 226
Hanoi 218
São Paulo 213
Dearborn 199
Moscow 198
Salt Lake City 191
Tallinn 191
Milan 190
Nanchang 188
San Diego 184
Shanghai 171
Boardman 153
Changsha 152
Shenyang 140
Hebei 133
San Francisco 133
London 132
Turku 116
Orem 109
Santa Clara 107
Tianjin 105
Jinan 94
Rio de Janeiro 91
Jakarta 88
Tampa 87
Tokyo 83
Elk Grove Village 82
Brno 80
Dong Ket 80
Nuremberg 78
Brooklyn 74
Secaucus 73
Jiaxing 70
Hangzhou 68
Stockholm 68
Rome 66
Belo Horizonte 64
Dalmine 62
Johannesburg 60
Chennai 57
Lappeenranta 57
Romola 57
Brasília 56
Frankfurt am Main 56
Orange 56
Toronto 56
Montreal 55
Phoenix 55
Kunming 54
Poplar 54
Verona 54
Da Nang 53
Guangzhou 53
Atlanta 52
Brussels 52
Lancaster 52
Kocaeli 51
Zhengzhou 50
Boston 49
Haiphong 47
Paris 46
Baghdad 45
Amsterdam 44
Denver 44
Tashkent 44
Curitiba 43
Sterling 43
Mexico City 42
Totale 44.065
Salva come PNG Salva come JPEG
Nome #
Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer 787
Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience. 378
Adrenocortical carcinoma xenograft in zebrafish embryos as model to study the in vivo cytotoxicity of abiraterone acetate 306
GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity 295
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 260
Eight‐week interval in flushing and locking port‐a‐cath in cancer patients: A single‐institution experience and systematic review 252
Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures 251
In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures☆ 247
Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma 246
Excess of second tumors in denosumab-treated patients: A metabolic hypothesis 246
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study 246
Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. 244
Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review 244
Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up† 238
IN VITRO ANTITUMOR ACTIVITY OF PROGESTERONE IN HUMAN ADRENOCORTICAL CARCINOMA 226
Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case 225
Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells 221
Pros-IT CNR: an Italian prostate cancer monitoring project 220
Immunotherapy failure in adrenocortical cancer: where next? 220
Clinical and histological prognostic factors of recurrent and/or metastatic salivary gland adenoid cystic carcinoma 220
Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy 212
Neoadjuvant treatment approach: The rosetta stone for breast cancer? 211
Genetic Polymorphisms as Possible Factors Involved in the Onset of Anthracycline-Induced Cardiomyopathy 208
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials 208
Management of Severe Cushing Syndrome Induced by Adrenocortical Carcinoma with Abiraterone Acetate: A Case Report 207
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement 205
Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma 203
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer 201
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents 201
Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy 199
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. 197
Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria 197
Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy 196
Should Adjuvant Weekly Paclitaxel Be Considered Less Efficacious Than Anthracyclines Plus Cyclophosphamide for Lower Risk Patients With Early-Stage Breast Cancer? 195
Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study 192
The guanine nucleotide exchange factor VAV2 as a new prognostic parameter in adrenocortical carcinoma 190
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509) 189
Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity 189
Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines 189
Regression of advanced neuroendocrine tumors among patients receiving placebo 187
Palbociclib inhibits proliferation of human adrenocortical tumor cells 186
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer 186
Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options 186
Inhibition of Survivin Is Associated with Zoledronic Acid-induced Apoptosis of Prostate Cancer Cells 184
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer 184
Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis 180
Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature 180
Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report 179
828PBONE METASTASES FROM RCC ARE NOT ALWAYS ASSOCIATED WITH A POOR PROGNOSIS 179
A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report 179
Antineoplastic Activity of Artemisinin in Adrenocortical Carcinoma 178
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 177
Biological bases of radical prostatectomy in the management of prostate cancer patients with oligometastatic disease 177
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients 177
Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies. 176
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement 175
Effect of primary letrozole treatment on tumor expression of mTOR and HIF-1α and relation to clinical response 175
Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. 172
Adjuvant bisphosphonates in patients with breast cancer: Does the potency matter? 172
Osimertinib in EGFR Mutation–Positive Advanced NSCLC 172
The Circadian Rhythm of Breakthrough Pain Episodes in Terminally-ill Cancer Patients 171
CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs) 171
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. 170
Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines? 169
Management of patients with castration-resistant prostate cancer (CRPC): results of an Italian survey using the delphi method 168
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature 168
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013) 168
Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients 168
Serum vitamin D and prostate cancer prognosis: The story continues 167
When should everolimus be administered in the natural history of pancreatic neuroendocrine tumors? 167
Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer? 166
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study 166
Exemestane with ovarian suppression in premenopausal breast cancer. 166
A current perspective on treatment of adrenocortical carcinoma 165
Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis 165
Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports 165
Anti-Angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients 164
Cost-effectiveness of model-based eligibility for lung cancer screening in the routine clinical practice 162
Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. 161
5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma 161
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME) 161
Leptomeningeal metastasis from solid tumors: a diagnostic and therapeutic challenge. 161
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† 161
Gonadal function in male patients with metastatic renal cell cancer treated with sunitinib: Effects of testosterone replacement on quality of life. 159
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors 158
An unusual case of a well-differentiated neuroendocrine tumour of the ileum with peritoneal carcinomatosis: A case report 155
Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference 155
Cisplatin Cytotoxicity in Human Testicular Germ Cell Tumor Cell Lines Is Enhanced by the CDK4/6 Inhibitor Palbociclib 155
Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma 153
Molecular target agents in adrenocortical carcinoma: rationale and difficulties in trial design 153
Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance 153
The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures 152
MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects 152
Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy worse radical cystectomy outcomes in frails 151
Aspergillosis superinfection as a cause of death of crizotinib-induced interstitial lung disease successfully treated with high-dose corticosteroid therapy 150
Baseline prognostic factors affecting survival in recurrent and/or metastatic salivary gland adenoid cystic carcinoma 150
Abiraterone and increased survival in metastatic prostate cancer 149
Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study 149
Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): An European Network for the Study of Adrenal Tumor (ENSAT) study 148
Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment. 147
Totale 19.522
Salva come PNG Salva come JPEG
Categoria #
all - tutte 306.932
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 306.932
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.209 0 0 0 0 0 0 0 0 0 1.174 650 385
2021/20223.503 274 702 93 213 50 182 214 234 194 349 267 731
2022/20232.586 497 83 74 178 191 712 10 212 347 44 115 123
2023/20243.948 180 96 316 217 207 696 109 145 1.039 118 48 777
2024/202510.895 98 74 98 1.510 1.168 737 591 293 1.088 803 2.697 1.738
2025/202618.370 1.636 2.770 1.934 3.138 1.553 1.223 2.697 784 1.253 1.382 0 0
Totale 65.766